Cannabidiol is under clinical development by Ananda Scientific and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Cannabidiol is under development for the treatment of schizoprenia, neuropathic pain, opioid replacement and withdrawal, opioid use disorder, Rett syndrome, chronic radiculopathic pain syndromes, post-traumatic stress disorder (PTSD), type 2 diabetes, unspecified cardiovascular disorders, social anxiety disorder and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate was under development for the treatment of inflammatory bowel disease. It is administered through oral route. It acts by targeting CB1 and CB2 receptors. The drug candidate is being developed based on liquid nano-sized delivery technology.

Ananda Scientific overview

Ananda Scientific improves health and the quality of life with oral, non-psychoactive products based on cannabis plant chemistry. The company is headquartered in Arapahoe, Colorado, the US

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.